Abstract
Although a number of appetite suppressants are now in clinical trials, the search for new anti-obesity drug targets continues. Recent advances in basic science have unveiled 2 new receptors that may prove to have potential in this field. They are the neuropeptide Y (NPY)-5 receptor and the peroxisome proliferator activated receptor (PPAR)-γ. These possible new approaches to the treatment of obesity were discussed at the 3rd IBC USA conference on ‘Obesity - Advances in Understanding and Treatment’ [ San Diego, US; September 1996 ].
Rights and permissions
About this article
Cite this article
Higgins, G. New targets may lead to novel classes of anti-obesity drugs. Inpharma Wkly. 1062, 7–8 (1996). https://doi.org/10.2165/00128413-199610620-00015
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-199610620-00015